Please use this identifier to cite or link to this item:
|Title:||Brain amyloid imaging.|
|Authors:||Rowe, Christopher C;Villemagne, Victor L|
|Affiliation:||Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia. firstname.lastname@example.org|
|Citation:||Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2011; 52(11): 1733-40|
|Abstract:||Imaging of brain β-amyloid plaques with (18)F-labeled tracers for PET will likely be available in clinical practice to assist the diagnosis of Alzheimer disease (AD). With the rapidly growing prevalence of AD as the population ages, and the increasing emphasis on early diagnosis and treatment, brain amyloid imaging is set to become a widely performed investigation. All physicians reading PET scans will need to know the complex relationship between amyloid and cognitive decline, how to best acquire and display images for detection of amyloid, and how to recognize the patterns of tracer binding in AD and other causes of dementia. This article will provide nuclear medicine physicians with the background knowledge required for understanding this emerging investigation, including its appropriate use, and prepare them for practical training in scan interpretation.|
|Internal ID Number:||21917849|
Alzheimer Disease.complications.metabolism.pathology.radionuclide imaging
Fluorine Radioisotopes.diagnostic use
Image Interpretation, Computer-Assisted
Mild Cognitive Impairment.complications.radionuclide imaging
Sensitivity and Specificity
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.